Alkeon Capital Management - 4D MOLECULAR THERAPEUTICS IN ownership

4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 78 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Alkeon Capital Management ownership history of 4D MOLECULAR THERAPEUTICS IN
ValueSharesWeighting
Q3 2021$16,243,000
+34.1%
602,225
+19.7%
0.03%
+50.0%
Q2 2021$12,110,000
-30.7%
502,926
+24.8%
0.02%
-30.8%
Q1 2021$17,479,000
+4.9%
402,926
+0.3%
0.03%
-3.7%
Q4 2020$16,658,000401,8850.03%
Other shareholders
4D MOLECULAR THERAPEUTICS IN shareholders Q4 2021
NameSharesValueWeighting ↓
Aquilo Capital Management, LLC 945,382$22,765,0005.92%
Octagon Capital Advisors LP 831,267$20,017,0004.15%
BVF INC/IL 2,005,862$48,301,0001.81%
Casdin Capital, LLC 1,115,555$26,863,0000.68%
Eagle Health Investments LP 57,090$1,375,0000.47%
Soleus Capital Management, L.P. 100,800$2,427,0000.37%
VIKING GLOBAL INVESTORS LP 3,937,914$94,825,0000.29%
ArrowMark Colorado Holdings LLC 1,029,897$24,800,0000.19%
Perceptive Advisors 750,512$18,072,0000.12%
Virtus ETF Advisers LLC 7,642$184,0000.08%
View complete list of 4D MOLECULAR THERAPEUTICS IN shareholders